Black Rock Inc. Sab Biotherapeutics, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.38 - $1.09 $21,800 - $62,533	-57,370 Reduced 52.15%	52,643 $43,000
Q1 2023 May 12, 2023	BUY	$0.42 - $0.75 $781 - $1,395	1,860 Added 1.72%	110,013 $48,000
Q4 2022 Feb 13, 2023	SELL	$0.54 - $9.8 $9,487 - $172,176	-17,569 Reduced 13.97%	108,153 $63,000
Q3 2022 Nov 14, 2022	SELL	$0.13 - $12.4 $224 - $21,377	-1,724 Reduced 1.35%	125,722 $88,000
Q2 2022 Aug 12, 2022	BUY	$1.11 - $3.46 $60,970 - $190,050	54,928 Added 75.74%	127,446 $185,000
Q1 2022 May 12, 2022	BUY	$1.78 - $8.5 $1,619 - $7,735	910 Added 1.27%	72,518 $273,000
Q4 2021 Feb 10, 2022	BUY	$7.3 - $11.24 $522,738 - $804,873	71,608 New	71,608 $559,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $172M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.